Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Endothelial VEGFR-2 Activation Precedes Severe Mucosal Injury in TNBS-Induced Colitis.

International journal of molecular sciences·2026

Same author

Mesenchymal stromal cells and neuroinflammation: a multimodal approach to neuroprotection and future therapeutic horizons.

Translational neurodegeneration·2026

Same author

A cell line-derived, immune-competent neurospheroid model to study neuroinflammation and human brain disorders.

Frontiers in immunology·2026

Same author

Beyond traditional models: microfluidic technologies for engineering the human placenta <i>in vitro</i>.

Frontiers in bioengineering and biotechnology·2026

Same author

Correction: Extracellular Matrix-Guided Islet Cell Transplantation Results in Improved Glycemic Control in a NOD-SCID Mouse Model.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026

Same author

RNA cargo profiling of muscle extracellular vesicles identifies candidate biomarkers of disease activity and muscle degeneration in FSHD.

Journal of translational medicine·2026

Search research articles

Related Experiment Video

Updated: Nov 19, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Perinatal Cells: A Promising COVID-19 Therapy?

Andrea Papait^1,2, Anna Cargnoni², Michal Sheleg³

¹Department of Life Science and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.

Frontiers in Bioengineering and Biotechnology

|February 1, 2021

Summary

Perinatal cells show promise for treating COVID-19 complications like acute respiratory distress syndrome (ARDS) and sepsis. Their immunomodulatory and reparative properties offer potential therapeutic benefits for severe cases.

Keywords:

PLacental eXpanded coronavirus-induced disease 2019 mesenchymal stromal cells perinatal severe acute respiratory distress syndrome coronavirus-2

More Related Videos

Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions

Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions

Published on: November 27, 2017

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model

Published on: October 31, 2012

Related Experiment Videos

Last Updated: Nov 19, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions

Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions

Published on: November 27, 2017

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model

Published on: October 31, 2012

Area of Science:

Immunology
Regenerative Medicine
Infectious Diseases

Background:

COVID-19 pandemic necessitates novel therapeutic strategies due to lack of specific treatments.
Severe COVID-19 can lead to acute respiratory distress syndrome (ARDS) and sepsis.
Cytokine storm and disseminated intravascular coagulation exacerbate lung and organ damage.

Purpose of the Study:

To review the characteristics of perinatal cells.
To highlight their potential benefits for COVID-19 patients.
To explore their use in treating ARDS and sepsis.

Main Methods:

Literature review of perinatal cell properties.
Analysis of immunomodulatory and reparative effects.
Evaluation of antibacterial and antiviral actions.

Main Results:

Perinatal cells possess significant immunomodulatory potential.
They demonstrate a favorable safety profile.
These cells can reduce fibrosis and promote tissue repair.

Conclusions:

Perinatal cells offer a promising therapeutic avenue for COVID-19.
Their properties are beneficial for managing ARDS and sepsis.
Further research into their clinical application is warranted.